Molecular Partners Presents Updated Results of MP0250 in Patients with Relapsed/Refractory Multiple Myeloma (MM) at American Society of Hematology Annual Meeting

Zurich-Schlieren, Switzerland, December 7, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, today announced a poster presentation at the American Society of Hematology 61st Annual Meeting in Orlando, FL, highlighting the activity of its tri-specific DARPin® drug candidate, MP0250, in patients undergoing...

read more

Encouraging Additional Phase 3 Data Presented for Abicipar, and Start of Phase 1 Trial for MP0310, the First Immuno-oncology DARPin® with a Novel Therapeutic Design

Zurich-Schlieren, October 31, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, announced today its Interim Management Statement for the period ending September 30, 2019. “Abicipar represents the first DARPin® therapeutic to be accepted for review by FDA...

read more

Neurimmune Welcomes Biogen’s News on Clinical Benefit of Aducanumab

Zurich, Switzerland – October 22, 2019 – Neurimmune welcomes the news that Biogen plans regulatory filing for aducanumab in Alzheimer's disease based on a new analysis of a larger data set from Phase 3 studies. Neurimmune discovered aducanumab together with a team of researchers at the University of Zurich. In...

read more